• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
The risk of coronary artery disease after heart transplantation is increased in patients receiving low-dose cyclosporine, regardless of blood cyclosporine levels.接受低剂量环孢素治疗的心脏移植患者,无论其血液中环孢素水平如何,患冠状动脉疾病的风险都会增加。
Clin Cardiol. 1997 Sep;20(9):767-72. doi: 10.1002/clc.4960200911.
2
Cyclosporine does not enhance the development of accelerated coronary artery disease: experimental study in a rat cardiac transplant model.环孢素不会促进加速性冠状动脉疾病的发展:大鼠心脏移植模型的实验研究。
J Heart Lung Transplant. 2002 Apr;21(4):425-34. doi: 10.1016/s1053-2498(01)00371-0.
3
Low-dose cyclosporine treatment fails to prevent coronary luminal narrowing after heart transplantation.低剂量环孢素治疗无法预防心脏移植后冠状动脉管腔狭窄。
J Heart Lung Transplant. 1996 Jun;15(6):612-9.
4
Cyclosporine reduction in the presence of everolimus: 3-month data from a Canadian pilot study of maintenance cardiac allograft recipients.在依维莫司存在的情况下减少环孢素:来自加拿大一项心脏移植受者维持治疗试点研究的3个月数据。
J Heart Lung Transplant. 2008 Feb;27(2):197-202. doi: 10.1016/j.healun.2007.11.565.
5
Increased morbidity and high variability of cyclosporine levels in pediatric heart transplant recipients.小儿心脏移植受者中环孢素水平的发病率增加及高度变异性。
J Heart Lung Transplant. 2000 Apr;19(4):343-9. doi: 10.1016/s1053-2498(00)00061-9.
6
Cyclosporine mitigates graft coronary artery disease in murine cardiac allografts: description and validation of a novel fully allogeneic model.环孢素减轻小鼠心脏同种异体移植中的移植冠状动脉疾病:一种新型完全同种异体模型的描述与验证
J Heart Lung Transplant. 2005 Apr;24(4):446-53. doi: 10.1016/j.healun.2004.01.022.
7
Efficacy and side-effects of cyclosporine dose monitoring with levels 6 h after the morning dose in heart transplant patients.心脏移植患者晨服环孢素6小时后血药浓度监测的疗效及副作用
Clin Transplant. 1997 Oct;11(5 Pt 1):399-405.
8
The importance of early cyclosporine levels in pediatric kidney transplantation.早期环孢素水平在小儿肾移植中的重要性。
Clin Transplant. 1996 Dec;10(6 Pt 1):482-6.
9
Safety, tolerability and efficacy of cyclosporine microemulsion in heart transplant recipients: a randomized, multicenter, double-blind comparison with the oil based formulation of cyclosporine--results at six months after transplantation.环孢素微乳剂在心脏移植受者中的安全性、耐受性及疗效:与环孢素油剂的随机、多中心、双盲对照研究——移植后6个月的结果
Transplantation. 1999 Sep 15;68(5):663-71. doi: 10.1097/00007890-199909150-00012.
10
Cardiac allograft rejection late after transplantation is a risk factor for graft coronary artery disease.心脏移植术后晚期发生的心脏移植排斥反应是移植后冠状动脉疾病的一个危险因素。
Transplantation. 1998 Feb 27;65(4):538-43. doi: 10.1097/00007890-199802270-00015.

引用本文的文献

1
Cardiovascular effects of immunosuppression agents.免疫抑制剂的心血管效应。
Front Cardiovasc Med. 2022 Sep 21;9:981838. doi: 10.3389/fcvm.2022.981838. eCollection 2022.

本文引用的文献

1
Low-dose cyclosporine treatment fails to prevent coronary luminal narrowing after heart transplantation.低剂量环孢素治疗无法预防心脏移植后冠状动脉管腔狭窄。
J Heart Lung Transplant. 1996 Jun;15(6):612-9.
2
Risk factors for chronic rejection in renal allograft recipients.肾移植受者慢性排斥反应的危险因素。
Transplantation. 1993 Apr;55(4):752-6; discussion 756-7. doi: 10.1097/00007890-199304000-00013.
3
Long-term efficacy and safety of cyclosporine in renal-transplant recipients.环孢素在肾移植受者中的长期疗效与安全性。
N Engl J Med. 1994 Aug 11;331(6):358-63. doi: 10.1056/NEJM199408113310604.
4
Abbreviated three-point kinetic profile in the 12-hour area under the curve for pharmacokinetic monitoring of cyclosporine.用于环孢素药代动力学监测的12小时曲线下面积的简化三点动力学曲线
Transplant Proc. 1994 Oct;26(5):2807-8.
5
Impact of cyclosporine dose on long-term outcome after heart transplantation.
Transplant Proc. 1994 Oct;26(5):2710-2.
6
Low dosage of cyclosporine and increased occurrence of chronic rejection in heart-transplanted patients.心脏移植患者中低剂量环孢素与慢性排斥反应发生率增加
Transplant Proc. 1994 Oct;26(5):2581-2.
7
Comparison of three administration schedules of cyclosporine A in humans.
Transplant Proc. 1994 Oct;26(5):2509-10.
8
Impact of cyclosporine dose on renal allograft function in an Asian population.环孢素剂量对亚洲人群肾移植功能的影响。
Transplant Proc. 1994 Oct;26(5):2507-8.
9
Cyclosporine pharmacokinetics and variability from a microemulsion formulation--a multicenter investigation in kidney transplant patients.环孢素微乳剂的药代动力学及变异性——一项针对肾移植患者的多中心研究
Transplantation. 1994 Sep 27;58(6):658-63.
10
Development of coronary artery disease in cardiac transplant patients receiving immunosuppressive therapy with cyclosporine and prednisone.接受环孢素和泼尼松免疫抑制治疗的心脏移植患者冠状动脉疾病的发展
Circulation. 1987 Oct;76(4):827-34. doi: 10.1161/01.cir.76.4.827.

接受低剂量环孢素治疗的心脏移植患者,无论其血液中环孢素水平如何,患冠状动脉疾病的风险都会增加。

The risk of coronary artery disease after heart transplantation is increased in patients receiving low-dose cyclosporine, regardless of blood cyclosporine levels.

作者信息

Gamba A, Mamprin F, Fiocchi R, Senni M, Troise G, Ferrazzi P, Ferrara R, Corbetta G

机构信息

Department of Cardiac Surgery, Ospedali Riuniti di Bergamo, Italy.

出版信息

Clin Cardiol. 1997 Sep;20(9):767-72. doi: 10.1002/clc.4960200911.

DOI:10.1002/clc.4960200911
PMID:9294668
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6655631/
Abstract

BACKGROUND

Coronary artery disease (CAD) of allografted hearts is the main cause of late mortality after cardiac transplant, but its etiology is still undetermined.

HYPOTHESIS

This study was undertaken to evaluate the relevance of several risk factors, including cyclosporine (CsA) dose and blood CsA levels, to the incidence of CAD.

METHODS

In 163 heart transplants performed between November 1985 and August 1994 at our Institution, CAD was diagnosed by coronary angiography or at postmortem examination. Patients in whom postmortem examination or coronary angiography was not performed, as well as those < 15 years of age and those who died within 1 month of surgery, were excluded from the study. The following risk factors were analyzed: recipient age, gender, pretransplant diagnosis, donor age, number of human leukocyte antigen (HLA)-AB mismatches, cytomegalovirus serology, mear serum cholesterol and triglyceride levels, the number of treated acute rejections, mean weighted CsA dose (CsA dosew and weighted blood CsA levels (blood CsA levelw).

RESULTS

Coronary artery disease was diagnosed in 32 patients (19.6%). A low mean CsA dosew was the only significant predictor for CAD at multivariate analysis (p < 0.01): there was no correlation with blood CsA levelw. In the patients receiving a CsA dosew > 4 mg/kg/day, the 8.9 year probability of their remaining CAD free was 69% [confidence interval (CI) 50-87%] in comparison with 31% (CI 0-65%) in patients receiving a CsA dosew < 4 mg/kg/day.

CONCLUSION

In our experience, a low CsA maintenance dose is the main risk factor for CAD, irrespective of blood CsA levels.

摘要

背景

心脏移植术后晚期死亡的主要原因是移植心脏的冠状动脉疾病(CAD),但其病因仍未明确。

假说

本研究旨在评估包括环孢素(CsA)剂量和血CsA水平在内的多种危险因素与CAD发生率的相关性。

方法

1985年11月至1994年8月在我们机构进行的163例心脏移植中,CAD通过冠状动脉造影或尸检诊断。未进行尸检或冠状动脉造影的患者,以及年龄<15岁和术后1个月内死亡的患者被排除在研究之外。分析了以下危险因素:受者年龄、性别、移植前诊断、供者年龄、人类白细胞抗原(HLA)-AB错配数、巨细胞病毒血清学、平均血清胆固醇和甘油三酯水平、治疗的急性排斥反应次数、平均加权CsA剂量(CsA剂量w)和加权血CsA水平(血CsA水平w)。

结果

32例患者(19.6%)诊断为冠状动脉疾病。多因素分析显示,低平均CsA剂量w是CAD的唯一显著预测因素(p<0.01):与血CsA水平w无相关性。在接受CsA剂量w>4mg/kg/天的患者中,其无CAD生存8.9年的概率为69%[置信区间(CI)50-87%],而接受CsA剂量w<4mg/kg/天的患者为31%(CI 0-65%)。

结论

根据我们的经验,低CsA维持剂量是CAD的主要危险因素,与血CsA水平无关。